Clinical Trials Browser

nilotinib × Gastrointestinal × Clear all

NCT05185947 2025-03-07

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

Phase 2 Active not recruiting

GastrointestinalGynecologic

Appendiceal Neoplasms, Genital Neoplasms, Female, Necrosis, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms

NCT01863745 2024-08-19

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Phase 2 Completed

15 enrolled 7 charts

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT01735955 2024-02-08

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Phase 4 Completed

57 enrolled 8 charts

GastrointestinalLymphoidMyeloidOther hematologic neoplasmSarcoma

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Piebaldism, Gastrointestinal Stromal Tumors, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00135005 2020-12-08

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

Phase 1 Completed

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00976612 2020-01-07

Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01871311 2019-02-08

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

Phase 1 Terminated

GastrointestinalHead & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Colorectal Neoplasms

NCT02774512 2017-10-06

ZAK-0

Phase EARLY_PHASE1 Withdrawn

Gastrointestinal

Colonic Neoplasms

NCT00633295 2017-06-22

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor

Phase 2 Completed

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01110668 2017-02-28

Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Phase 2 Completed

GastrointestinalSarcoma

Disease Progression, Gastrointestinal Stromal Tumors

NCT00718562 2017-02-23

Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

Phase 2 Completed

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01289028 2017-01-02

Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

Phase 3 Completed

125 enrolled 11 charts

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT00785785 2016-06-16

ENESTg1

Phase 3 Completed

644 enrolled 8 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00751036 2014-03-26

MACS0375

Phase 3 Terminated

94 enrolled 10 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00441155 2013-05-13

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Phase 1 Completed

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT00782834 2013-04-22

07060

Phase 2 Terminated

13 enrolled 8 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01270893 2012-08-02

Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)

Phase 2 Withdrawn

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT00471328 2012-06-12

ENEST

Phase 3 Completed

248 enrolled 17 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors